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Abstract
Original Article
IntroductIon
The outcome of tuberculous meningitis (TBM) is 
greatly influenced by the time to treatment initiation. 
Therefore, establishing a rapid diagnosis is crucial. 
A rapid clinical score (RCS) was found to have good 
sensitivity and specificity in differentiating TBM from viral 
meningitis (VM).[1]
The aim of our study was to retrospectively validate the 
RCS in distinguishing TBM from VM in people who are at 
increased risk of tuberculosis and evaluate its performance 
in differentiating TBM from cryptococcal meningitis (CM).
Methods
We performed a retrospective study of patients admitted with 
a diagnosis of aseptic meningitis between January 2012 and 
December 2015, to a referral hospital for infectious diseases, 
from Bucharest, Romania. We reviewed medical records of all 
adults with clinical symptoms of meningitis (fever, headache, 
nausea/vomiting, neck stiffness), who had a clear appearance 
of cerebrospinal fluid (CSF) and abnormal CSF findings: 
pleocytosis ≥5 cells/mm3, the absence of bacteria either on 
Gram stain and/or in routine culture, and/or negative latex 
agglutination tests for bacterial antigens.
Patients were considered to have definite TBM if they had a 
microbiological confirmation of Mycobacterium tuberculosis 
from a CSF sample by either detection of acid-fast bacilli on 
CSF smear, positive culture for M. tuberculosis, and/or positive 
GeneXpert MTB/RIF (Cepheid, Sunnyvale, USA). Probable 
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and possible TBM were defined according to a published 
consensus case definition and scoring system.[2]
We included patients with VM in HIV-noninfected patients. 
Patients were considered to have VM if bacterial and other 
noninfectious causes of meningitis were excluded, a viral cause 
was identified, or the outcome was favorable under antiviral 
or supportive treatment.
Diagnosis of CM in HIV-infected patients was based on positive 
India ink stain, culture, and/or cryptococcal antigen assay.
We excluded patients with possible TBM, prior antibiotic 
therapy, malignancy, and autoimmune disorders with CNS 
involvement.
We evaluated a previously described RCS that uses four 
variables: duration of symptoms before admission (DSBA), 
neurological stage according to the Medical Research 
Council (MRC) definitions, CSF to blood glucose ratio, and 
CSF protein to assess the probability of TBM in patients with 
clear CSF meningitis. Neurological stages were classified 
according to the MRC definitions as follows: Stage I - fully 
conscious and no focal deficits; Stage II - confusion, lethargy, 
focal neurological signs such as cranial nerve palsies; Stage 
III - stuporous or comatose, multiple cranial nerve palsies, or 
complete hemiparesis.[3]
The RCS confers 3 points for a DSBA ≥5 days or CSF/blood 
glucose ratio <0.5, 2 points for neurological Stages II and III, 
and 1 point for CSF protein >100 mg/dl. A score of at least 
6 points is suggestive of TBM with a sensitivity of 92% and 
a specificity of 94%.[1] We calculated sensitivity, specificity, 
positive predictive value (PPV), and negative predictive 
value (NPV) for the cutoff of 6 and 9 points (all four criteria 
were present).
Statistical analysis
Sensitivity and specificity were calculated with CAT maker. 
The diagnostic value of the score was assessed by calculating 
the area under the receiver operating characteristics (ROCs) 
curves with SPSS version 19.0 (Statistical Package for the 
Social Science Inc., Chicago, IL, USA). The study was 
approved by the Hospital Ethics Committee.
results
We identified 31 patients with TBM, 62 patients with VM, and 
18 patients with CM. Among patients with TBM, there were 
21 (67.7%) patients with definite and 10 (32.3%) with probable 
TBM. HIV infection had been diagnosed in 14 (45.2%) 
patients with TBM. Seven (50%) HIV-infected patients were 
intravenous drug users. TBM diagnosis was confirmed by 
culture in 6 (19%) patients, GeneXpert MTB/RIF in 7 (23%) 
patients, and both culture and GeneXpert MTB/RIF in 8 (26%) 
patients.
We compared clinical, laboratory, and cerebral imaging 
findings from the 31 definite and probable TBM patients with 
those of the 62 patients with VM [Table 1].
When comparing TBM with CM, a DSBA ≥5 days was 
noted in 30 (96.8%) patients with TBM versus 12 (67%) 
patients with CM (OR: 0.14 [95% CI: 0.01–1.36], 
P = 0.09); presence of neurological Stage II or III in 
22 (71%) patients with TBM versus 14 (78%) patients with 
CM (OR: 1.27 [95% CI: 0.25–6.27], P = 1); CSF/blood 
glucose ratio <0.5 in 28 (90.3%) patients with TBM versus 
13 (72%) patients with CM (OR: 0.2 1 [95% CI: 0.02–2.13], 
P = 0.35); CSF protein >100 mg/dl in 26 (83.9%) patients 
with TBM versus 7 (38.9%) patients with CM (OR: 0.11 
[95% CI: 0.02–0.68], P = 0.02).
We calculated the sensitivity, specificity, PPV, and NPV for 
differentiating TBM from VM using a cutoff of at least 6 points 
or at least 9 points and from CM using a cutoff of at least 
6 points [Table 2].
dIscussIon
In this study, we aimed to validate a previously described RCS 
for TBM meningitis, in patients hospitalized during the four 
years that followed the time period when the original study 
was conducted. We could show a similar sensitivity of the RCS 
but a lower specificity.
In countries with a high prevalence of tuberculosis, 
differentiating TBM from other causes of acute lymphocytic 
meningitis might be an important issue. Since direct 
microscopic examination of CSF has a low sensitivity, results 
of culture are delayed, and molecular techniques continue 
to have a variable sensitivity; easy-to-use diagnostic scores 
might still play a role for identifying patients with TBM. 
The Xpert MTB/RIF which has been approved since 2010 
for the diagnosis of pulmonary tuberculosis showed high 
specificity (99%) but relatively low sensitivity (55%–59%) 
in detecting M. tuberculosis in CSF; larger volumes of 
concentrated CSF with centrifugation increases the sensitivity 
of Xpert MTB/RIF to that of CSF culture (72%).[4-6] In addition, 
these tests may not be always available.
We found that the RCS had a modest specificity (81.1%) but 
a high sensitivity of 96.7%  for differentiating TBM from 
VM. When all four criteria from the RCS were present, the 
specificity increased at 100%. The area under the ROC curve 
for TBM probabilities was similar in the original studied group 
and in the population on which RCS was described (0.949, 
0.977, respectively).
Although in the population in which the RCS was originally 
developed, only 9% of TBM patients were HIV infected; in 
the present study, 45% of TBM patients were HIV infected. 
This might be associated with an increase among new HIV 
cases attributed to injecting drug use, from <3% before 2010 
to 19%–30% starting with 2011.[7] Thus, the score maintains a 
good sensitivity for identifying TBM regardless of HIV status.
Since persons living with HIV (PLHIV) are at increased 
risk for both TBM and CM, a RCS that would differentiate 
between the two conditions would be helpful in clinical 
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Table 1: Comparison of the clinical and laboratory characteristics in tuberculous and viral meningitis
VM (n=62), n (%) 
or median (range)
TBM (definite and probable) 
(n=31), n (%) or median (range)
OR (95% CI) P
Patient history and clinical features
Age (years) 34 (23-46) 38 (30-54) 0.230
Male sex 23 (37.1) 20 (64.5) 3.08 (1.25-7.57) 0.016
DSBA (days) 4 (3-7) 14 (7-28) 0.006
DSBA ≥5 days 26 (41.9) 30 (96.8) 0.04 (0.009-0.19) <0.001
Fever 56 (90.3) 25 (80.6) 2.24 (0.65-7.63) 0.205
Headache 56 (90.3) 29 (93.5) 1.55 (0.29-8.18) 0.603
Neck rigidity 47 (75.8) 30 (96.7) 0.11 (0.01-0.89) 0.017
Cranial nerve involvement 2 (3.2) 7 (22.5) 0.11 (0.02-0.59) 0.006
Seizures 1 (1.6) 7 (22.5) 0.05 (0.01-0.49) 0.002
Focal neurological deficit 2 (3.2) 4 (12.9) 0.22 (0.03-1.3) 0.093
Psychiatric symptoms 4 (6.4) 10 (32.2) 0.14 (0.04-0.51) 0.002
Impaired consciousness 6 (9.6) 22 (71) 0.04 (0.01-0.12) <0.001
Neurological stage
Stage I 56 (90.3) 9 (29.1) 22.8 (7.2-71.6) <0.001
Stage II 1 (1.6) 14 (45.1) 0.02 (0.002-0.16) <0.001
Stage III 5 (8.1) 8 (25.8) 0.25 (0.07-0.85) 0.028
In-hospital mortality 0 7 (22.5) Not applicable <0.001
Laboratory findings
CSF cell number (cells/mm3) 245 (122-450) 166 (58-250) 0.018
Mononuclear predominance (≥50%) 56 (90.3) 24 (77.4) 2.72 (0.82-8.95) 0.116
CSF/blood glucose ratio <0.5 21 (33.9) 28 (90.3) 0.08 (0.02-0.27) <0.001
CSF protein (mg/dL) 93 (56-143) 231 (150-326) 0.001
CSF protein>100 mg/dL 25 (40.3) 26 (83.9) 0.11 (0.03-0.33) <0.001
Cerebral imaging findings
Hydrocephalus 0 5 (16.1) Not applicable 0.139
Cerebral infarction 0 5 (16.1) Not applicable 0.139
OR = Odds ratio, CI = Confidence interval, DSBA = Duration of symptoms before admission, CSF = Cerebrospinal fluid, TBM = Tuberculous meningitis, 
VM = Viral meningitis
Table 2: Diagnostic accuracy of rapid clinical score for the diagnosis of tuberculous meningitis
Sensitivity (%) 
(95% CI)
Specificity (%) 
(95% CI)
PPV (%) 
(95% CI)
NPV (%) 
(95% CI)
Area under 
the ROC curve 
(95% CI)
TBM (n=31) versus VM (n=62) score ≥6 96.7 (83.3-99.9) 81.1 (68.0-90.5) 75.0 (63.1-84.0) 97.7 (86.1-99.6) 0.949 (0.90-0.99)
TBM (n=31) versus VM (n=62) score=9 51.6 (33.0-69.8) 100 (93.2-100) 100 77.9 (71.0-83.5) NA
TBM (n=14) versus CM (n=18) in HIV-infected score ≥6 86.6 (59.5-98.3) 27.7 (9.69-53.4) 50 (41.3-58.6) 71.4 (36.0-91.7) 0.669 (0.48-0.85)
TBM = Tuberculous meningitis, VM = Viral meningitis, CM = Cryptococcal meningitis, CI = Confidence interval, ROC = Receiver operating 
characteristic, NA = Not available, NPV = Negative predictive value, PPV = Positive predictive value
practice. However, when applying the RCS in PLHIV for 
differentiating between TBM and CM, sensitivity was modest, 
while specificity was poor suggesting that the scoring system 
cannot be used for this purpose. Regarding CM and TBM in 
HIV patients, although several studies have identified clinical 
and laboratory features associated with TBM (fever, neck 
stiffness, altered consciousness, CSF neutrophil predominance, 
CSF pleocytosis, CSF protein >1 g/L) or with CM (nausea 
and vomiting, high CSF opening pressure, low CSF white 
blood cell count), these features are nonspecific and can be 
present in both conditions making an accurate differentiation 
between TBM and CM on this basis challenging.[8,9] However, 
CM diagnosis can easily be made using rapid and accessible 
tests that have been shown to have excellent sensitivities and 
specificities of 98%–99% when performed on both blood and 
CSF samples.[10]
The main limitations of our study are its retrospective nature 
and the small number of patients.
conclusIon
The RCS might be a useful tool in patients with high risk of 
TBM in differentiating TBM from VM. Although this RCS 
cannot be used to differentiate between TBM and CM in 
HIV-infected patients, there are other highly sensitive and 
easily accessible methods available for diagnosing CM.
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